- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01200043
Metabolic Impact of Fructose Restriction in Obese Children (SUCRE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent studies suggest that specific types of macronutrients in the diet may have selective effects on nutrient absorption, insulin sensitivity, and lipid metabolism. Elucidation of the metabolic impact of specific dietary components may well result in improved efficacy of lifestyle approaches to reduce obesity and metabolic diseases. Despite similar fructose consumption, the phenotype of co-morbidities is different between African Americans and Latinos. Latino and Caucasian children manifest worsened dyslipidemia and non-alcoholic fatty liver disease (NAFLD), while African American children manifest worsened insulin resistance and hypertension. We have also documented in adults that a reduction in de novo lipogenesis (DNL; production of new lipids) in the liver and liver fat content, and improvement in hepatic insulin sensitivity were achieved by substitution of complex carbohydrate for fructose; but these changes appeared less dramatic in African American compared to Latino or Caucasian subjects. These divergent findings suggest ethnic and race-specific differences of fructose metabolism and disposition.
To determine whether fructose is a contributor to metabolic co-morbidity in children, we will conduct a convenience cohort within-subject intervention with repeated measures, stratified by racial/ethnic group (Latinos vs. African Americans vs. Caucasians). The intervention will consist of restricting fructose ingestion only to naturally-occurring fructose in fruits and vegetables (approximately 15 gm/day for 10 days), by substituting complex carbohydrate for excess dietary fructose, while maintaining neutral energy balance. We anticipate fructose restriction to differentially improve co-morbidities in different racial/ethnic groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- UCSF
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- African-American, Latino, and Caucasian boys and girls. Ethnicity is to be determined by self-report. Utilizing the US Census Bureau procedures, participants will be asked two questions, the first regarding ethnicity and the second on race. Subjects will be given the opportunity to select more than one racial category.
- Ages 8 to 18 yr. The minimum age cutoff is due to our desire not to sedate younger children for the magnetic resonance spectroscopy scan or magnetic resonance scan (MRS, MRI). We chose to study these groups because they are most affected by metabolic syndrome and manifest the greatest morbidities; yet their presentations are different from each other.
The following criteria are modified from the National Cholesterol Education Program's Adult Treatment Panel and the World Health Organization definition of metabolic syndrome. Waist circumference is not an adequate predictor of visceral adiposity in children. Also, no normative values have been developed nor is this measurement consistent between racial and ethnic groups. Body mass index (BMI), however, correlates strongly with both visceral lipid depot and blood pressure. The definition of hypertension is greater than the 95th percentile for sex and age as designated in the 1996 Task Force Report on High Blood Pressure in Children and Adolescents.
- Obesity, as defined by BMI z-score of 2.0 or greater, or above the 97th percentile for age and sex; and weight ≥40 kg.
- Hyperinsulinemia (fasting insulin >15 µU/mL), or insulin resistant (HOMA > 4.3). See details below.
- At least one of the following: systolic blood pressure above the 95th percentile for age and sex, or triglyceride level above the 95th percentile for age, sex and race or ethnic group as established by the 1998 National Heart, Lung, and Blood Institute Growth and Health Study.
Exclusion Criteria:
- History of disorders other than obesity that may affect insulin levels, such as Cushing's syndrome, diabetes mellitus, or depression.
- Medications that may affect insulin sensitivity or hepatic lipid content, e.g. metformin, steroids, atypical antipsychotics, anti depressants, statins, Vitamin E, thyroid medications, anti-hypertensives, weight loss medications, oral contraceptives.
- Pregnancy or lactation.
- Surgical procedures for obesity.
- History consistent with obstructive sleep apnea.
- Implants including intracranial surgical clips, pacemakers, and other metals or implants that preclude MR scanning.
- Claustrophobia.
- Inability to fit within the MR bore: shoulder to shoulder width of greater than 58 cm or anterior-posterior length greater than 35 cm (magnet bore size limitation).
- Weight greater than 320 pounds (MRS table weight limitation).
- Eating disorders.
- Smoking or alcohol use. Subjects will answer the two questions on the Alcohol Query Form. Any consumption of more than 2 drinks per month will
- Vegan diet.
- All subjects with known diabetes mellitus according to the 1997 ADA criteria will be excluded. However, subjects with known impaired glucose tolerance (fasting glucose 101-125, and 2-hour post-prandial glucose level between 141-200) can remain eligible.
- Syndromic patients (e.g. Prader-Willi, Bardet-Biedl) will be excluded, as it is likely that the reasons for their obesity may be neurologic or single-point mutations, and are likely to be different from those causing the Metabolic Syndrome.
- Subjects who are found to be hypothyroid by clinical exam or by evaluation of thyroid function tests on first visit to the WATCH Clinic will receive L-thyroxine for three months, with documentation of adequate replacement, prior to enrollment in the protocol.
- Subjects with a history of hepatitis will be excluded from the study. However, patients with NAFLD, as determined by Dr. P. Rosenthal (Ped. Hepatology, UCSF), may participate. Upper cutoffs for AST and ALT will be 5 times the upper limit of normal for the UCSF laboratory.
- Subjects with any history of renal disease will be excluded.
- Subjects who have a fever or an active infection will be postponed until their infection remits.
- Emancipated minors will be excluded, as there will be no parental supervision and monitoring over the subject's diet during the 9 days of fructose restriction.
- Females who have achieved menarche will have a urine pregnancy test at the time of their DEXA scans. A positive pregnancy test will lead to exclusion of the data from further analysis. Results of a positive pregnancy test will be transmitted to the minor only, and the parents will be told only that the subject does not qualify for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: fructose restriction
Isocaloric fructose restricted diet for 10 days
|
fruits and vegetables only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intrahepatic fat content
Time Frame: 10 days
|
We anticipate fructose restriction to reduce intrahepatic fat, exclusive of calories
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
insulin resistance
Time Frame: 10 days
|
We anticipate fructose restriction will improve insulin sensitvity exclusive of calories
|
10 days
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, Patterson BW, Gugliucci A, Lustig RH, Mulligan K. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017 Sep;153(3):743-752. doi: 10.1053/j.gastro.2017.05.043. Epub 2017 Jun 1.
- Gugliucci A, Lustig RH, Caccavello R, Erkin-Cakmak A, Noworolski SM, Tai VW, Wen MJ, Mulligan K, Schwarz JM. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis. 2016 Oct;253:171-177. doi: 10.1016/j.atherosclerosis.2016.06.048. Epub 2016 Jul 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCSF-2845
- R01DK089216 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on fructose restriction diet
-
University of DelawareRecruitingInflammation | Blood PressureUnited States
-
University of LausanneCentre Hospitalier Universitaire VaudoisCompleted
-
Rockefeller UniversityRobert C. Atkins Foundation; The Rogosin InstituteCompletedEnd-stage Renal DiseaseUnited States
-
University Hospital of North NorwayNordlandssykehuset HFCompletedIrritable Bowel Syndrome | Fructose MalabsorptionNorway
-
Washington University School of MedicineCompleted
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Crohn...Completed
-
Guangzhou Sport UniversityUnknownChildhood Obesity | Adolescent ObesityChina
-
Chin HsuCompleted
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI); University of Southern California and other collaboratorsCompletedObesity | Type 2 Diabetes | Chronic Disease of Cardiovascular SystemUnited States